Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Schering Sues Zhejiang Hisoar Pharmaceutical For Patent Infringement

This article was originally published in PharmAsia News

Executive Summary

Schering Corp. has sued three local firms in China - Zhejiang Hisoar Pharmaceutical, Zhejiang Hisoar Pharmaceutical Sales and Saniver Ltd - for patent infringement of its florfenicol antibiotics. Schering demands an immediate stop of its drug infringement and asks for RMB 500,000 in damages, on top of legal costs. Hisoar denies the charges and claims florfenicol is one of its key products. Analysts observe that many drug patent infringement lawsuits stem from the nation's low level of drug R&D. Domestic generic drugs increasingly threaten the market share of pharmaceutical MNCs' patented drugs, spurring the owners to file suits to contain their technology. Analysts observe that IP remains a sore point for local pharmaceutical industry's move toward internationalization. (Click here for more - Chinese Language)

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts